TRAPANI, DARIO
TRAPANI, DARIO
Dipartimento di Oncologia ed Emato-Oncologia
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 C. Valenza, E. Nicolò, M. Mongillo, D. Trapani, J. Katrini, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, J. Villa, S. Derio, M. Lapresa, F. Gigli, G. Parma, E. Omodeo Salè, E. Derenzini, G. Curigliano, N. Colombo
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
2025 K. Venetis, C. Frascarelli, L.B. Bielo, G. Cursano, R. Adorisio, M. Ivanova, E. Mane, V. Peruzzo, A. Concardi, M. Negrelli, M. D'Ercole, F.M. Porta, Y. Zhan, A. Marra, D. Trapani, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, N. Fusco
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
2024 A. Esposito, E. Crimini, C. Criscitiello, C. Belli, R. Scafetta, R. Scalia, G. Castellano, E. Giordano, J. Katrini, L. Ascione, L. Boscolo Bielo, M. Repetto, A. Marra, D. Trapani, G.M. Varano, D. Maiettini, P. Della Vigna, F. Orsi, E. Guerini Rocco, N. Fusco, G. Curigliano
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center
2024 C. Valenza, T.M. De Pas, A. Gaeta, G. Castellano, C. Santoro, A. Corona, G. Chiappini, G. Vivanet, D. Trapani, S. Coppola, F. Conforti, D. Mattar, S. Gandini, P. Veronesi, E. Pennacchioli, G. Curigliano
A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials
2024 I. Pourmir, H.K. Van Halteren, R. Elaidi, D. Trapani, F. Strasser, G. Vreugdenhil, M. Clarke
Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates
2024 S. Natangelo, D. Trapani, C. Koukoutzeli, L. Boscolo Bielo, G. Marvaso, B.A. Jereczek-Fossa, G. Curigliano
WHO model list of essential in vitro diagnostics: strengthening diagnostics capacity to transform health care for all
2024 D. Trapani, P.J. Garcia, L. Schroeder, R. Abdul-Ghani, A. Hansali, P.N. Offutalu, W. Sewell, S. Shakoor, L. Yunfeng, N. Hashimoto, F.G. Moussy, A. Aceves Capri, K. Fleming
Cardiotoxicity of Agents Used in Patients With Breast Cancer
2024 P. Zagami, D. Trapani, E. Nicolò, C. Corti, C. Valenza, C. Criscitiello, G. Curigliano, L.A. Carey
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations
2024 L. Boscolo Bielo, E. Guerini Rocco, D. Trapani, P. Zagami, B. Taurelli Salimbeni, A. Esposito, C. Belli, E. Crimini, K. Venetis, E. Munzone, N. Fusco, C. Criscitiello, A. Marra, G. Curigliano
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
2024 L. Cantini, D. Trapani, L. Guidi, L. Boscolo Bielo, R. Scafetta, M. Koziej, L. Vidal, K.S. Saini, G. Curigliano
Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems
2024 D. Horgan, M. Van den Bulcke, U. Malapelle, G. Troncone, N. Normanno, E.D. Capoluongo, A. Prelaj, C. Rizzari, D. Trapani, J. Singh, M. Kozaric, J. Longshore, M. Ottaviano, S. Boccia, G. Pravettoni, I. Cattaneo, N. Malats, R. Buettner, K. Lekadir, F. de Lorenzo, P. Hofman, R. De Maria
Biomarkers for antibody-drug conjugates in solid tumors
2024 J. Katrini, L. Boldrini, C. Santoro, C. Valenza, D. Trapani, G. Curigliano
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2024 S. Loibl, F. André, T. Bachelot, C.H. Barrios, J. Bergh, H.J. Burstein, M.J. Cardoso, L.A. Carey, S. Dawood, L. Del Mastro, C. Denkert, E.M. Fallenberg, P.A. Francis, H. Gamal-Eldin, K. Gelmon, C.E. Geyer, M. Gnant, V. Guarneri, S. Gupta, S.B. Kim, D. Krug, M. Kater, I. Meattini, M. Morrow, W. Janni, S. Paluch-Shimon, A. Partridge, P. Poortmans, L. Pusztai, M.M. Regan, J. Sparano, T. Spanic, S. Swain, S. Tjulandin, M. Toi, D. Trapani, A. Tutt, B. Xu, G. Curigliano, N. Harbeck
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
2024 E. Guerini-Rocco, K. Venetis, G. Cursano, E. Mane, C. Frascarelli, F. Pepe, M. Negrelli, E. Olmeda, D. Vacirca, A. Ranghiero, D. Trapani, C. Criscitiello, G. Curigliano, C. Rolfo, U. Malapelle, N. Fusco
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence
2024 M. Ivanova, C. Pescia, D. Trapani, K. Venetis, C. Frascarelli, E. Mane, G. Cursano, E. Sajjadi, C. Scatena, B. Cerbelli, G. D'Amati, F.M. Porta, E. Guerini-Rocco, C. Criscitiello, G. Curigliano, N. Fusco
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms
2024 C. Valenza, M. Mongillo, F. Gigli, D. Trapani, J. Katrini, E. Nicolò, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, S. Derio, M. Lapresa, G. Parma, E. Derenzini, G. Curigliano, N. Colombo
Grading of recommendations, assessment, development and evaluations concept 7: issues and insights linking guideline recommendations to trustworthy essential medicine lists
2024 T. Piggott, L. Moja, K. Jenei, T. Kredo, N. Skoetz, R. Banzi, D. Trapani, T. Leong, M. Mccaul, J.N. Lavis, E.A. Akl, F. Nonino, A. Iorio, J. Laurson-Doube, B.D. Huttner, H.J. Schünemann
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
2023 C. Valenza, G. Rizzo, M.I. Passalacqua, L. Boldrini, C. Corti, D. Trapani, G. Curigliano
Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
2023 D. Trapani, E. Crimini, J. Sandoval, G. Curigliano
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano